Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.

doi:10.1002/ijc.70554

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.

International journal of cancer - 1 Nov 2026

Geidel Glenn, Lowinus Theresa, Metzger Patrick, Czurda Rebecca, Schipperges Vincent, Paul Ulrike, Rünger Alessandra, Kött Julian, Heidrich Isabel, Lehr Saskia, Kühn Julia, Becker Heiko, Miething Cornelius, Werner Martin, Laßmann Silke, Duyster Justus, Brummer Tilman, Simon Ronald, Alsdorf Winfried, Christopeit Maximilian, Bokemeyer Carsten, Eyerich Kilian, Schneider Stefan W, Rafei David, Börries Melanie, Meiss Frank, Gebhardt Christoffer

Abstract excerpt

Despite therapeutic advancements, approximately 50% of advanced melanoma patients succumb to metastatic disease. Molecular tumor boards (MTB) aim to identify targetable molecular alterations to guide individualized treatment strategies. Yet, real-world data on patient selection, referral timing, recommendation rates, implementation, and clinical impact remain limited. In this exploratory retrospective bicenter...

Read the complete abstract on PubMed

Topics

Humans
Melanoma
Retrospective Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Germany

Male

Middle Aged

Aged

Adult

Mutation

Precision Medicine

Aged, 80 and over

Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42141746
DOI: 10.1002/ijc.70554
PMCID: PMC13548000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.PMID 42141746Read ↗

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.Semantic proximity Read ↗

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity Read ↗

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.Semantic proximity Read ↗

Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.Semantic proximity Read ↗

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesSemantic proximity Read ↗

Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.Semantic proximity Read ↗

Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios.Semantic proximity Read ↗

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.Semantic proximity Read ↗

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterSemantic proximity Read ↗

Unlocking precision oncology by establishing a nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer: the BALLETT studySemantic proximity Read ↗

Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer.Semantic proximity Read ↗

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.